RPL7P21

Across TCGA pan-cancer cohorts, RPL7P21 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated RPL7P21 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher RPL7P21 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL7P21 expression acts as an unfavorable survival marker, although some lineages such as LUAD and ESCA show a favorable association.

MESO, UVM, and BLCA are the cancer types where RPL7P21 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.266	0.508	<.001	78	view →
UVM	DFS	Tertile	III,IV	0.174	0.889	.001	41	view →
BLCA	DFS	Quartile	IV	0.305	0.478	.004	23	view →
KICH	DFS	Median	II,III,IV	0.559	0.955	.001	22	view →
LUAD	DFS	Tertile	IV	0.829	0.208	.006	18	view →
ESCA	DFS	Quartile	II,III,IV	0.649	0.334	.001	16	view →
KIRP	OS	Median	II,III,IV	0.312	0.736	.010	15	view →
CHOL	DFS	Quartile	II,III,IV	0.107	0.478	.010	12	view →
STAD	DFS	Quartile	IV	0.111	0.545	.014	12	view →
LUSC	OS	Tertile	II,III,IV	0.741	0.572	.019	11	view →
UCEC	DFS	Median	All	0.864	0.915	.011	10	view →
GBM	DFS	Median	All	0.307	0.206	.019	7	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

RPL7P21–MESO (OS)

Open the MESO breakdown →